The report “Biosimulation Market by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), by Application (Drug Discovery & Development, Preclinical, Clinical Trial), by End Users - Global Forecast to 2020”, the biosimulation market is expected to reach USD 2,107.99 Million by 2020 from USD 1,034.93 Million in 2015, growing at a CAGR of 15.29% between 2015 and 2020.
Chicago, IL -- (SBWIRE) -- 08/18/2015 -- Browse 75 market data tables and 64 figures spread through 150 pages and in-depth TOC on "Biosimulation Market"
http://www.marketsandmarkets.com/Market-Reports/biosimulation-market-838.html
Early buyers will receive 10% customization on this report.
The report provides a detailed overview of the major drivers, restraints, and opportunities impacting the global biosimulation market along with the estimates and forecasts of the revenue and market share analysis.
The global biosimulation market is poised to witness rapid growth between 2015 and 2020. A strong trend of R&D investments in biotechnology and pharmaceutical industries will majorly drive the biosimulation market. Other growth drivers include the need to curtail costs, growth in the biologics and biosimilars markets, and increased use of personalized medicine, technological advancements, and periodic product upgradation.
Get The PDF Brochure:
http://www.marketsandmarkets.com/pdfdownload.asp?id=838
The market is segmented on the basis of product, application, and end user. By product, the market includes software and services. The software segment is further classified into molecular modeling and simulation software, PBPK modeling and simulation software, PK/PD modeling and simulation software, trail design software, toxicity prediction software, and other software (QSP, visualizing and analytical software). The services segment includes in-house and external/contract services. Software will hold the largest share of the biosimulation market in 2015, while services will grow at the highest CAGR.
The applications included in this report are drug discovery, drug development, and others. The drug development segment is further classified into preclinical testing and clinical trials. The drug discovery segment is divided into target identification & validation and lead identification & optimization. The drug development segment will hold the largest share of the biosimulation market in 2015. The other applications segment (defense, industrial bioprocessing, nutraceuticals, and agri-food production) is expected to be the fastest growing.
End users included in this report are academic and government research institutes, pharmaceutical and biotechnology companies, contract research organizations (CROs), regulatory authorities and other end users (defense, nutraceuticals companies, and food and agricultural companies). Of these, the pharmaceutical and biotechnology companies will hold the largest share of the biosimulation market in 2015. Pharmaceutical and biotechnology companies are expected to form the fastest-growing end-user segment.
Talk To Our Research Analysts for More Information:
http://www.marketsandmarkets.com/speaktoanalyst.asp?id=838
The geographic segments included in this report are the North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to hold the largest share of this market in 2015, while Europe is expected to grow at the fastest rate. Growth in the European biosimulation market will primarily be driven by increased government funding and the large number of pharmaceuticals and biotechnology companies in this region.
Major players in the global biosimulation market are Certara USA, Inc. (U.S.), Simulation Plus Inc. (U.S.), Dassault Systèmes SA (France), Schrödinger Inc. (U.S.), Advanced Chemistry Development, Inc. (Canada), Chemical Computing Group, Inc. (Canada), Physiomics PLC (U.K.), Entelos Holding Corporation (U.S.), Rhenovia Pharma Ltd. (France), and Genedata AG (Switzerland).
About MarketsandMarkets
MarketsandMarkets is world's No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.
M&M's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
Subscribe Reports from Healthcare Domain @ http://www.marketsandmarkets.com/Subscription.html
Contact:
Mr. Rohan
1 South Dearborn Street,
21st Floor, Chicago,
Illinois, 60603, United States,
Tel: 888-600-6441
Email: sales@marketsandmarkets.com
Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/healthcareit
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets